Periodontal Attachment Loss, Periodontal Disease, AVDC Stage 3, Periodontal Disease, AVDC Stage 4, Periodontal Diseases, Periodontal Inflammation
Conditions
Keywords
periodontitis, lasers, prospective, plasminogen activator inhibitor 1, tissue plasminogen activator, low-level laser therapy, periodontal treatment
Brief summary
The present study aimed to investigate the effects of low-level laser therapy (LLLT) as an adjunct to non-surgical periodontal treatment (NSPT) on the plasminogen-activating system in Stage 3-4, Grade C periodontitis patients.
Detailed description
Limited data is available regarding the effects of various periodontal treatment protocols on GCF t-PA and PAI-1 levels, and the extent to which LLLT in conjunction with NSPT affects these levels in patients with Stage 3-4, Grade C periodontitis is unknown. Therefore, this study measured standard clinical outcomes and GCF t-PA and PAI-1 levels in patients with Stage 3-4 Grade, C periodontitis in order to assess the use of LLLT as an adjunct to standard NSPT. This split-mouth study was conducted with 15 Stage 3-4, Grade C periodontitis patients and 15 healthy individuals matched for age and sex. Participants were grouped as follows: Periodontitis/NSPT (Sham); Periodontitis/NSPT+LLLT (LLLT); Periodontally Healthy (Control). LLLT was applied following NSPT and again on post-treatment Days 2 and 7. Clinical parameters were recorded at baseline (i.e. before NSPT) and on Day 30. Gingival crevicular fluid (GCF) samples were collected at baseline and during follow-up visits on Days 7, 14 and 30. GCF t-PA and PAI-1 levels were measured with ELISA.
Interventions
standart periodontal therapy
adjunctive application of low level laser therapy to non-surgical periodontal treatment
Sponsors
Study design
Intervention model description
a split-mouth randomized controlled clinical study
Eligibility
Inclusion criteria
* Stage 3-4, Grade C periodontitis (at least one site with probing depth (PD) and clinical attachment level (CAL) ≥5 mm in their incisors and/or first molars and at least 6 other teeth with similar PD and CAL measurements, with alveolar bone loss confirmed by radiography; familial aggregation; * presence of ≥16 teeth; * no periodontal treatment in the 6 months prior to data collection; * non-smoker
Exclusion criteria
* systemic problems, including a medical history of cancer, rheumatoid arthritis, diabetes mellitus, or cardiovascular disease; * compromised immune system; * pregnancy, menopause, or lactation; * ongoing drug therapy that might affect the clinical characteristics of periodontitis; * use of systemic antimicrobials during the 6 weeks prior to data collection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the change in GCF tissue plasminogen activator | baseline and during follow-up visits on Days 7, 14 and 30. | Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit. Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis. |
| the change in GCF plasminogen activator inhibitor 1 | baseline and during follow-up visits on Days 7, 14 and 30. | Gingival crevicular fluid (GCF) samples were collected before SRP treatment and on days 7, 14 and 30 of follow- up and the change of the related mediator at those time points. The Amount of the related mediator were evaluated using enzyme- linked immunosorbent assay \[ELISA\] kit. Total amounts (pg/30 s) of the mediator collected from each sample in a 30- second period were calculated and recorded for analysis. |
Countries
Turkey (Türkiye)